# Computer-Aided Design of Peptidomimetic Inhibitors of Falcipain-3: QSAR and Pharmacophore Models

^{1}

^{2}

^{3}

^{4}

^{5}

^{*}

## Abstract

**:**

_{com}) and the experimentally measured ${\mathrm{IC}}_{50}^{\mathrm{exp}}$. Apart from the structure-based relationship, a ligand-based quantitative pharmacophore model (PH4) of novel PEP analogues where substitutions were directed by comparative analysis of the active site interactions was derived using the proposed bound conformations of the PEPx. This provided structural information useful for the design of virtual combinatorial libraries (VL), which was virtually screened based on the 3D-QSAR PH4. The end results were predictive inhibitory activities falling within the low nanomolar concentration range.

## 1. Introduction

## 2. Materials and Methods

#### 2.1. Biological Activities of Compounds Included in the Training and Validation Sets

#### 2.2. Molecular Modeling

#### 2.3. Molecular Mechanics

#### 2.4. Conformational Search

#### 2.5. Solvation Gibbs Free Energy

#### 2.6. Calculation of the Entropic Term

#### 2.7. Binding Affinity Calculations

#### 2.8. Interaction Energy Calculations

#### 2.9. Pharmacophore (PH4) Modeling

#### 2.10. Generation of the Virtual Library

^{−5}Å and a dielectric constant of 4 using the CHARMm force field were set, as described in Section 2.3.

#### 2.11. In Silico Screening

## 3. Results and Discussion

#### 3.1. Selection of Training and Validation (or Test) Data Sets

#### 3.2. Obtained QSAR Model

#### 3.3. Inhibitor Binding Modes

#### 3.4. Ligand-Based 3D-QSAR PH4 Model of FP3 Inhibition

^{2}) falls to an interval from 0.90 to 0.99. The first PH4 hypothesis with the best RMSD and R

^{2}was retained for further analysis. The statistical data for the set of hypotheses (costs, RMSD, R

^{2}) are listed in Table 4. The geometry of the Hypo1 pharmacophore of FP3 inhibition is displayed in Figure 5. Table 5 lists the regression equation (Table 3) for ${\mathrm{pIC}}_{50}^{\mathrm{exp}}$ vs. ${\mathrm{pIC}}_{50}^{\mathrm{pre}}$ estimated from Hypo1 with related indicators such as ${\mathrm{R}}^{2}$, ${\mathrm{R}}_{\mathrm{xv}}^{2}$, Fisher F-test, $\sigma $ and $\alpha $, while Figure 6 displays a plot of regression equation for ${\mathrm{pIC}}_{50}^{\mathrm{exp}}\mathrm{vs}.{\mathrm{pIC}}_{50}^{\mathrm{pre}}$. To check the consistency of the generated pharmacophore model, we have computed the ratio of predicted and observed activities $({\mathrm{pIC}}_{50}^{\mathrm{pre}}/({\mathrm{pIC}}_{50}^{\mathrm{exp}}$) for the validation set. The computed ratios are as follows: PEP26 (1.01), PEP28 (1.01), PEP36 (1.01) all of them relatively close to one, which documents the substantial predictive power of the regression for the best PH4 model.

#### 3.5. Library Design and ADME Focusing

_{1}to R

_{4}of the appropriate scaffold to provide a combinatorial library of the size: ${\mathrm{R}}_{1}\times {\mathrm{R}}_{2}\times {\mathrm{R}}_{3}\times {\mathrm{R}}_{4}={19}^{4}=130,321$ PEPAs.

#### 3.6. Screening PEPs Virtual Library Using the Obtained in Silico Model

#### 3.7. Analysis of New Inhibitors

## 4. Conclusions

## Author Contributions

## Funding

## Data Availability Statement

## Acknowledgments

## Conflicts of Interest

## References

- Bekono, B.D.; Ntie-Kang, F.; Owono Owono, L.C.; Megnassan, E. Targeting cysteine proteases from plasmodium falciparum: A general overview, rational drug design and computational approaches for drug discovery. Curr. Drug Targets
**2018**, 19, 501–526. [Google Scholar] [CrossRef] [PubMed] - Dye, C. Global epidemiology of tuberculosis. Lancet
**2006**, 367, 938–940. [Google Scholar] [CrossRef] - WHO. World Malaria Report; WHO: Geneva, Switzerland, 2015. [Google Scholar]
- Rosenthal, P.; Sijwali, P.; Singh, A.; Shenai, B. Cysteine proteases of malaria parasites: Targets for chemotherapy. Curr. Pharm. Des.
**2002**, 8, 1659–1672. [Google Scholar] [CrossRef] [PubMed] - Yeh, I.; Altman, R. Drug targets for plasmodium falciparum: A Post-Genomic Review/Survey. Mini-Rev. Med. Chem.
**2006**, 6, 177–202. [Google Scholar] [CrossRef] [PubMed] - White, S.W.; Zheng, J.; Zhang, Y.-M.; Rock, C.O. The structural biology of type ii fatty acid biosynthesis. Annu. Rev. Biochem.
**2005**, 74, 791–831. [Google Scholar] [CrossRef] - Zhang, Y.-M.; Lu, Y.-J.; Rock, C.O. The reductase steps of the type II fatty acid synthase as antimicrobial targets. Lipids
**2004**, 39, 1055–1060. [Google Scholar] [CrossRef] [PubMed] - Elliott, D.A.; McIntosh, M.T.; Hosgood, H.D.; Chen, S.; Zhang, G.; Baevova, P.; Joiner, K.A. Four distinct pathways of hemoglobin uptake in the malaria parasite plasmodium falciparum. Proc. Natl. Acad. Sci. USA
**2008**, 105, 2463–2468. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Liu, J.; Gluzman, I.Y.; Drew, M.E.; Goldberg, D.E. The role of plasmodium falciparum food vacuole plasmepsins. J. Biol. Chem.
**2004**, 280, 1432–1437. [Google Scholar] [CrossRef] [Green Version] - Blackman, M. Proteases involved in erythrocyte invasion by the malaria parasite function and potential as chemotherapeutic targets. Curr. Drug Targets
**2000**, 1, 59–83. [Google Scholar] [CrossRef] - Eggleson, K.K.; Duffin, K.L.; Goldberg, D.E. Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum. J. Biol. Chem.
**1999**, 274, 32411–32417. [Google Scholar] [CrossRef] [Green Version] - Klemba, M.; Gluzman, I.; Goldberg, D.E. A Plasmodium falciparum dipeptidyl aminopeptidase I participates in vacuolar hemoglobin degradation. J. Biol. Chem.
**2004**, 279, 43000–43007. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Coterón, J.M.; Catterick, D.; Castro, J.; Chaparro, M.J.; Díaz, B.; Fernández, E.; Ferrer, S.; Gamo, F.J.; Gordo, M.; Gut, J.; et al. Falcipain inhibitors: Optimization studies of the 2-pyrimidinebcarbonitrile lead series†. J. Med. Chem.
**2010**, 53, 6129–6152. [Google Scholar] [CrossRef] - Sijwali, P.S.; Koo, J.; Singh, N.; Rosenthal, P.J. Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of plasmodium falciparum. Mol. Biochem. Parasitol.
**2006**, 150, 96–106. [Google Scholar] [CrossRef] [PubMed] - Ramjee, M.K.; Flinn, N.S.; Pemberton, T.P.; Quibell, M.; Wang, Y.; Watts, J.P. Substrate mapping and inhibitor profiling of falcipain-2, falcipain-3 and berghepain-2: Implications for peptidase anti-malarial drug discovery. Biochem. J.
**2006**, 399, 47–57. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Ang, K.K.H.; Ratnam, J.; Gut, J.; Legac, J.; Hansell, E.; Mackey, Z.B.; Skrzypczynska, K.M.; Debnath, A.; Engel, J.C.; Rosenthal, P.J.; et al. Mining a cathepsin inhibitor library for new antiparasitic drug leads. PLoS Negl. Trop. Dis.
**2011**, 5, e1023. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Chibale, K.; Musonda, C. The synthesis of parasitic cysteine protease and trypanothione reductase inhibitors. Curr. Med. Chem.
**2003**, 10, 1863–1889. [Google Scholar] [CrossRef] [PubMed] - Desai, P.V.; Patny, A.; Gut, J.; Rosenthal, P.J.; Tekwani, B.; Srivastava, A.; Avery, M. Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. J. Med. Chem.
**2006**, 49, 1576–1584. [Google Scholar] [CrossRef] - Rosenthal, P.J.; Wollish, W.S.; Palmer, J.T.; Rasnick, D. Antimalarial effects of peptide inhibitors of a plasmodium falciparum cysteine proteinase. J. Clin. Investig.
**1991**, 88, 1467–1472. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Rosenthal, P.J.; Lee, G.K.; Smith, R.E. Inhibition of a plasmodium vinckei cysteine proteinase cures murine malaria. J. Clin. Investig.
**1993**, 91, 1052–1056. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Rosenthal, P.J.; Olson, J.E.; Lee, G.K.; Palmer, J.T.; Klaus, J.L.; Rasnick, D. Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors. Antimicrob. Agents Chemother.
**1996**, 40, 1600–1603. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Olson, J. Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorg. Med. Chem.
**1999**, 7, 633–638. [Google Scholar] [CrossRef] - Verissimo, E.; Berry, N.; Gibbons, P.; Cristiano, M.L.S.; Rosenthal, P.J.; Gut, J.; Ward, S.A.; O’Neill, P.M. Design and synthesis of novel 2-pyridone peptidomimetic falcipain 2/3 inhibitors. Bioorg. Med. Chem. Lett.
**2008**, 18, 4210–4214. [Google Scholar] [CrossRef] [PubMed] - Weldon, D.J.; Shah, F.; Chittiboyina, A.G.; Sheri, A.; Chada, R.R.; Gut, J.; Rosenthal, P.J.; Shivakumar, D.; Sherman, W.; Desai, P.; et al. Synthesis, biological evaluation, hydration site thermodynamics, and chemical reactivity analysis of α-keto substituted peptidomimetics for the inhibition of plasmodium falciparum. Bioorg. Med. Chem. Lett.
**2014**, 24, 1274–1279. [Google Scholar] [CrossRef] [PubMed] - Potshangbam, A.M.; Tanneeru, K.; Reddy, B.M.; Guruprasad, L. 3D-QSAR and molecular docking studies of 2-pyrimidinecarbonitrile derivatives as inhibitors against falcipain-3. Bioorg. Med. Chem. Lett.
**2011**, 21, 7219–7223. [Google Scholar] [CrossRef] - Desai, P.V.; Patny, A.; Sabnis, Y.; Tekwani, B.; Gut, J.; Rosenthal, P.; Srivastava, A.; Avery, M. Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge Database. J. Med. Chem.
**2004**, 47, 6609–6615. [Google Scholar] [CrossRef] [PubMed] - Shah, F.; Mukherjee, P.; Desai, P.; Avery, M. Computational approaches for the discovery of cysteine protease inhibitors against malaria and SARS. Curr. Comput. Aided-Drug Des.
**2010**, 6, 1–23. [Google Scholar] [CrossRef] [PubMed] - Shah, F.; Mukherjee, P.; Gut, J.; Legac, J.; Rosenthal, P.J.; Tekwani, B.L.; Avery, M.A. Identification of novel malarial cysteine protease inhibitors using structure-based virtual screening of a focused cysteine protease inhibitor library. J. Chem. Inf. Modeling
**2011**, 51, 852–864. [Google Scholar] [CrossRef] [PubMed] - Ghasemi, J.; Shiri, F.; Pirhadi, S.; Heidari, Z. Discovery of New potential antimalarial compounds using virtual screening of ZINC database. Comb. Chem. High Throughput Screen.
**2015**, 18, 227–234. [Google Scholar] [CrossRef] - Kerr, I.D.; Lee, J.H.; Farady, C.J.; Marion, R.; Rickert, M.; Sajid, M.; Pandey, K.C.; Caffrey, C.R.; Legac, J.; Hansell, E.; et al. Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J. Biol. Chem.
**2009**, 284, 25697–25703. [Google Scholar] [CrossRef] [Green Version] - Kerr, I.D.; Lee, J.H.; Pandey, K.C.; Harrison, A.; Sajid, M.; Rosenthal, P.J.; Brinen, L.S. Structures of falcipain-2 and falcipain-3 bound to small molecule inhibitors: Implications for substrate specificity‡. J. Med. Chem.
**2009**, 52, 852–857. [Google Scholar] [CrossRef] - Berman, H.M.; Bhat, T.N.; Bourne, P.E.; Feng, Z.; Gilliland, G.; Weissig, H.; Westbrook, J. The Protein Data Bank and the challenge of structural genomics. Nat. Struct. Biol.
**2000**, 7, 957–959. [Google Scholar] [CrossRef] - Accelrys, version 2.5; Discovery Studio: San Diego, CA, USA, 2009.
- Frecer, V.; Kabeláč, M.; De Nardi, P.; Pricl, S.; Miertuš, S. Structure-based design of inhibitors of NS
_{3}serine protease of hepatitis C virus. J. Mol. Graph. Model.**2004**, 22, 209–220. [Google Scholar] [CrossRef] - Frecer, V.; Jedinak, A.; Tossi, A.; Berti, F.; Benedetti, F.; Romeo, D.; Miertus, S. Structure based design of inhibitors of aspartic protease of HIV-1. Lett. Drug Des. Discov.
**2005**, 2, 638–646. [Google Scholar] [CrossRef] - Frecer, V.; Berti, F.; Benedetti, F.; Miertus, S. Design of peptidomimetic inhibitors of aspartic protease of HIV-1 containing –PheΨPro– core and displaying favourable ADME-related properties. J. Mol. Graph. Model.
**2008**, 27, 376–387. [Google Scholar] [CrossRef] - Frecer, V.; Seneci, P.; Miertus, S. Computer-assisted combinatorial design of bicyclic thymidine analogs as inhibitors of mycobacterium tuberculosis thymidine monophosphate kinase. J. Comput.-Aided Mol. Des.
**2010**, 25, 31–49. [Google Scholar] [CrossRef] [PubMed] - Dali, B.; Keita, M.; Megnassan, E.; Frecer, V.; Miertus, S. Insight into selectivity of peptidomimetic inhibitors with modified statine core for Plasmepsin II of Plasmodium falciparum over human cathepsin D. Chem. Biol. Drug Des.
**2012**, 79, 411–430. [Google Scholar] [CrossRef] - Megnassan, E.; Keita, M.; Bieri, C.; Esmel, A.; Frecer, V.; Miertus, S. Design of novel dihydroxynaphthoic acid inhibitors of Plasmodium falciparum lactate dehydrogenase. Med. Chem.
**2012**, 8, 970–984. [Google Scholar] [CrossRef] [PubMed] - Owono Owono, L.C.; Keita, M.; Megnassan, E.; Frecer, V.; Miertus, S. Design of thymidine analogues targeting thymidilate kinase of mycobacterium tuberculosis. Tuberc. Res. Treat.
**2013**, 2013, 1–13. [Google Scholar] [CrossRef] [Green Version] - Keita, M.; Kumar, A.; Dali, B.; Megnassan, E.; Siddiqi, M.I.; Frecer, V.; Miertus, S. Quantitative structure–activity relationships and design of thymine-like inhibitors of thymidine monophosphate kinase of mycobacterium tuberculosis with favourable pharmacokinetic profiles. RSC Adv.
**2014**, 4, 55853–55866. [Google Scholar] [CrossRef] - Kouassi, A.; Kone, M.; Keita, M.; Esmel, A.; Megnassan, E.; N’Guessan, Y.; Frecer, V.; Miertus, S. Computer-aided design of orally bioavailable pyrrolidine carboxamide inhibitors of enoyl-acyl carrier protein reductase of mycobacterium tuberculosis with favorable pharmacokinetic profiles. Int. J. Mol. Sci.
**2015**, 16, 29744–29771. [Google Scholar] [CrossRef] [Green Version] - Owono Owono, L.C.; Ntie-Kang, F.; Keita, M.; Megnassan, E.; Frecer, V.; Miertus, S. Virtually designed triclosan-based inhibitors of enoyl-acyl carrier protein reductase of mycobacterium tuberculosisand of Plasmodium falciparum. Mol. Inform.
**2015**, 34, 292–307. [Google Scholar] [CrossRef] [PubMed] - Esmel, A.; Keita, M.; Eugene, M.; Toï, B.; Frecer, V.; Miertus, S. Insight into binding mode of nitrile inhibitors of Plasmodium falciparum falcipain-3, QSAR and pharmacophore models, virtual design of new analogues with favorable pharmacokinetic profiles. J. Comput. Chem. Mol. Model.
**2017**, 2, 103–124. [Google Scholar] [CrossRef] [Green Version] - N’Guessan, A.; Megnassan, E.; Ziao, N.; Frecer, V.; N’Guessan, Y.T.; Miertus, S. Artemisinin-dipeptidyl vinyl sulfone hybrid inhibitors of plasmodium falciparum falcipain 2 with favorable pharmacokinetic profile. J. Drug Des. Dev.
**2017**, 1, 11–28. [Google Scholar] [CrossRef] - N’Guessan, H.; Megnassan, E. In silico design of phosphonic arginine and hydroxamic acid inhibitors of Plasmodium falciparum M17 Leucyl Aminopeptidase with favorable pharmacokinetic profile. J. Drug Des. Med. Chem.
**2017**, 3, 98. [Google Scholar] [CrossRef] [Green Version] - Kily Herve Fagnidi, Y.; Toi, B.; Megnassan, E.; Frecer, V.; Miertus, S. In silico design of plasmodium falciparum cysteine protease falcipain 2 inhibitors with favorable pharmacokinetic profile. J. Anal. Pharm. Res.
**2018**, 7, 298–309. [Google Scholar] [CrossRef] [Green Version] - Kouman, K.C.; Keita, M.; Kre N’Guessan, R.; Owono Owono, L.C.; Megnassan, E.; Frecer, V.; Miertus, S. Structure-based design and in silico screening of virtual combinatorial library of benzamides inhibiting 2-trans enoyl-acyl carrier protein reductase of Mycobacterium tuberculosis with favorable predicted pharmacokinetic profiles. Int. J. Mol. Sci.
**2019**, 20, 4730. [Google Scholar] [CrossRef] [Green Version] - Brooks, B.R.; Bruccoleri, R.E.; Olafson, B.D.; States, D.J.; Swaminathan, S.; Karplus, M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem.
**1983**, 4, 187–217. [Google Scholar] [CrossRef] - Accelrys, version 4.4; Materials Studio: San Diego, CA, USA, 2009.
- Gilson, M.; Honig, B. The inclusion of electrostatic hydration energies in molecular mechanics calculations. J. Comput.-Aided Mol. Des.
**1991**, 5, 5–20. [Google Scholar] [CrossRef] - Rocchia, W.; Sridharan, S.; Nicholls, A.; Alexov, E.; Chiabrera, A.; Honig, B. Rapid grid-based construction of the molecular surface and the use of induced surface charge to calculate reaction field energies: Applications to the molecular systems and geometric objects. J. Comput. Chem.
**2001**, 23, 128–137. [Google Scholar] [CrossRef] - BÖTtcher, C.J.F. NON-LINEAR EFFECTS. In Theory of Electric Polarization; Elsevier: Amsterdam, The Netherlands, 1973. [Google Scholar]
- Miertuš, S.; Scrocco, E.; Tomasi, J. Electrostatic interaction of a solute with a continuum. A direct utilizaion of ab initio molecular potentials for the prevision of solvent effects. Chem. Phys.
**1981**, 55, 117–129. [Google Scholar] [CrossRef] - Frecer, V.; Miertuš, S. Polarizable continuum model of solvation for biopolymers. Int. J. Quantum Chem.
**1992**, 42, 1449–1468. [Google Scholar] [CrossRef] - Fischer, S.; Smith, J.C.; Verma, C.S. Dissecting the vibrational entropy change on protein/ligand binding: Burial of a water molecule in bovine pancreatic trypsin inhibitor. J. Phys. Chem. B
**2001**, 105, 8050–8055. [Google Scholar] [CrossRef] - Schwarzl, S.M.; Tschopp, T.B.; Smith, J.C.; Fischer, S. Can the calculation of ligand binding free energies be improved with continuum solvent electrostatics and an ideal-gas entropy correction? J. Comput. Chem.
**2002**, 23, 1143–1149. [Google Scholar] [CrossRef] - Freire, E. Do enthalpy and entropy distinguish first in class from best in class? Drug Discov. Today
**2008**, 13, 869–874. [Google Scholar] [CrossRef] [PubMed] - Copeland, R.A.; Lombardo, D.; Giannaras, J.; Decicco, C.P. Estimating KI values for tight binding inhibitors from dose-response plots. Bioorg. Med. Chem. Lett.
**1995**, 5, 1947–1952. [Google Scholar] [CrossRef] - Frecer, V.; Miertus, S.; Tossi, A.; Romeo, D. Rational design of inhibitors for drug-resistant HIV-1 aspartic protease mutants. Drug Des. Discov.
**1998**, 15, 211–231. [Google Scholar] - Frecer, V.; Miertus, S. Interactions of ligands with macromolecules: Rational design of specific inhibitors of aspartic protease of HIV-1. Macromol. Chem. Phys.
**2002**, 203, 1650–1657. [Google Scholar] [CrossRef] - MOE. Molecular Operating Environment (MOE); Chemical Computing Group Inc.: Montreal, QC, Canada, 2014. [Google Scholar]
- Available Chemicals Directory. Available online: https://www.psds.ac.uk/acd (accessed on 12 July 2021).
- Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev.
**1997**, 23, 3–25. [Google Scholar] [CrossRef]

**Figure 1.**Chemical structures of training and validation sets of FP3 inhibitors obtained from literature [24].

**Figure 2.**Correlation plot between ${\mathrm{pIC}}_{50}^{\mathrm{exp}}$ and relative complexation Gibbs free energies $\u2206\u2206{\mathrm{G}}_{\mathrm{com}}$ of the training set of nine FP3 inhibitors.

**Figure 3.**Breakdown of interaction energy (kcal/mol) contribution between PEP32, PEP39, PEP40 and the most interacting residues of the FP3 active site.

**Figure 4.**Proposed binding mode of peptidomimetics inhibitors at the active site of FP3. Main favourable non-bond interactions depicted in 3D (

**left picture**) and 2D (

**right picture**) for the most active PEP39 (purple carbons atoms).

**Figure 5.**(

**a**) Features of the Hypo1 pharmacophore of FP3 inhibition; (

**b**) pharmacophore mapping by the most active of the training set PEP39; (

**c**) inter-features distances in Å; (

**d**) angles between features. Colours legend of features: hydrophobic (blue), hydrogen bond acceptor (green), hydrogen bond donor (purple), excluded volumes (grey).

**Figure 8.**The best virtual hit, analogue PEP-14-14-14-18 (with purple carbons atoms), mapped a PH4 Hypo 1.

**Figure 9.**Connolly surfaces (left) and 3D (right) schematic interaction diagrams of the 4 most potent analogues designed at the active site of PfFP3: (

**a**) PEP-17-03-14-10 (${\mathrm{IC}}_{50}^{\mathrm{pre}}$ = 0.29 nM); (

**b**) PEP-08-15-18-19 (${\mathrm{IC}}_{50}^{\mathrm{pre}}$ = 0.19 nM); (

**c**) PEP-13-06-04-19 (${\mathrm{IC}}_{50}^{\mathrm{pre}}$ = 0.10 nM); (

**d**) PEP-14-14-14-18 (${\mathrm{IC}}_{50}^{\mathrm{pre}}$= 0.07 nM).

**Table 1.**Training and validation sets of PEP inhibitors obtained from the literature [24].

Training Set ^{[a]} | ${\mathbf{M}}_{\mathbf{W}}{}^{\left[\mathbf{b}\right]}(\mathbf{g}\xb7{\mathbf{mol}}^{-1})$ | $\mathbf{I}{\mathbf{C}}_{50}^{\mathbf{exp}}{}^{\left[\mathbf{c}\right]}\left(\mathbf{nM}\right)$ |
---|---|---|

PEP23 (Ref) | 482.61 | 36,360 |

PEP27 | 452.56 | 910 |

PEP29 | 438.53 | 23,900 |

PEP32 | 466.54 | 47,230 |

PEP34 | 470.60 | 8220 |

PEP38 | 462.55 | 25,440 |

PEP39 | 440.50 | 60 |

PEP40 | 574.75 | 520 |

PEP41 | 498.61 | 3560 |

Validation Set ^{[a]} | ${M}_{W}$^{[b]}(g · mol^{−1}) | $I{C}_{50}^{exp}$^{[c]}(nM) |

PEP26 | 452.56 | 540 |

PEP28 | 450.54 | 20,180 |

PEP36 | 488.59 | 11,910 |

**Table 2.**Energy contributions towards $\u2206\u2206{\mathrm{G}}_{\mathrm{com}}$ for a dataset of PEP analogues against FP3 complexation Gibbs free energy and its components for the training and validation set of FP3 inhibitors. and experimental activity.

$\mathbf{T}\mathbf{r}\mathbf{a}\mathbf{i}\mathbf{n}\mathbf{i}\mathbf{n}\mathbf{g}\mathbf{S}\mathbf{e}\mathbf{t}{}^{\left[\mathbf{a}\right]}$ | $\mathbf{\u2206}\mathbf{\u2206}{\mathbf{H}}_{\mathbf{M}\mathbf{M}}{}^{\left[\mathbf{b}\right]}$ $\left(\mathbf{k}\mathbf{c}\mathbf{a}\mathbf{l}\xb7\mathbf{m}\mathbf{o}{\mathbf{l}}^{-1}\right)$ | $\mathbf{\u2206}\mathbf{\u2206}{\mathbf{G}}_{\mathbf{s}\mathbf{o}\mathbf{l}}{}^{\left[\mathbf{c}\right]}$ $\left(\mathbf{k}\mathbf{c}\mathbf{a}\mathbf{l}\xb7\mathbf{m}\mathbf{o}{\mathbf{l}}^{-1}\right)$ | $\mathbf{\u2206}\mathbf{\u2206}\mathbf{T}{\mathbf{S}}_{\mathbf{v}\mathbf{i}\mathbf{b}}{}^{\left[\mathbf{d}\right]}$ $\left(\mathbf{k}\mathbf{c}\mathbf{a}\mathbf{l}\xb7\mathbf{m}\mathbf{o}{\mathbf{l}}^{-1}\right)$ | $\mathbf{\u2206}\mathbf{\u2206}{\mathbf{G}}_{\mathbf{c}\mathbf{o}\mathbf{m}}{}^{\left[\mathbf{e}\right]}$ $\left(\mathbf{k}\mathbf{c}\mathbf{a}\mathbf{l}\xb7\mathbf{m}\mathbf{o}{\mathbf{l}}^{-1}\right)$ | $\mathbf{p}\mathbf{I}{\mathbf{C}}_{50}^{\mathbf{e}\mathbf{x}\mathbf{p}}{}^{\left[\mathbf{f}\right]}$ |
---|---|---|---|---|---|

PEP23 (Ref) | 0.00 | 0.00 | 0.00 | 0.00 | 4.44 |

PEP27 | −3.81 | −0.04 | -0.16 | −3.69 | 6.04 |

PEP29 | −0.39 | 0.13 | 1.45 | −1.71 | 4.62 |

PEP32 | 6.21 | −7.77 | -0.60 | −0.95 | 4.33 |

PEP34 | 5.97 | −9.92 | -0.51 | −3.44 | 5.09 |

PEP38 | 0.21 | 0.77 | 2.13 | −1.15 | 4.59 |

PEP39 | −2.07 | 0.12 | 3.98 | −5.92 | 7.22 |

PEP40 | −6.33 | 1.64 | 0.26 | −4.95 | 6.28 |

PEP41 | −3.24 | 1.16 | 0.42 | −2.50 | 5.45 |

$Validation$ $Set$ ^{[a]} | $\u2206\u2206{H}_{MM}$^{[b]}$\left(kcal\xb7mo{l}^{-1}\right)$ | $\u2206\u2206{G}_{sol}$^{[c]}$\left(kcal\xb7mo{l}^{-1}\right)$ | $\u2206\u2206{T}{S}_{vib}$^{[d]}$\left(kcal\xb7mo{l}^{-1}\right)$ | $\u2206\u2206{G}_{com}$^{[e]}$\left(kcal\xb7mo{l}^{-1}\right)$ | $Ratio$^{[g]} |

PEP26 | −7.67 | 1.39 | −0.78 | −5.50 | 1.07 |

PEP28 | −4.13 | 0.61 | −0.41 | −3.12 | 1.18 |

PEP36 | 6.51 | −10.30 | −0.15 | −3.64 | 1.18 |

^{[a]}For the chemical structures of the training/validation set of inhibitors see Figure 1.

^{[b]}$\u2206\u2206{\mathrm{H}}_{\mathrm{MM}}$ represents the relative enthalpic contribution to the Gibbs free energy change related to the intermolecular interactions in the enzyme–inhibitor complex derived by molecular mechanics (PEP23 (Ref) is the reference inhibitor ${\mathrm{I}}_{\mathrm{ref}}$):$\u2206\u2206{\mathrm{H}}_{\mathrm{MM}}=\left[{\mathrm{E}}_{\mathrm{MM}}\left\{\mathrm{E}:{\mathrm{I}}_{\mathrm{x}}\right\}-{\mathrm{E}}_{\mathrm{MM}}\left\{{\mathrm{I}}_{\mathrm{x}}\right\}\right]-\left[{\mathrm{E}}_{\mathrm{MM}}\left\{\mathrm{E}:{\mathrm{I}}_{\mathrm{ref}}\right\}-{\mathrm{E}}_{\mathrm{MM}}\left\{{\mathrm{I}}_{\mathrm{ref}}\right\}\right]\left(10\right)$.

^{[c]}$\u2206\u2206{\mathrm{G}}_{\mathrm{sol}}$ represents the relative solvation GFE contribution to the GFE of EI complex formation: $\u2206\u2206{\mathrm{G}}_{\mathrm{sol}}=\left[{\mathrm{G}}_{\mathrm{sol}}\left\{\mathrm{E}:{\mathrm{I}}_{\mathrm{x}}\right\}-{\mathrm{G}}_{\mathrm{sol}}\left\{{\mathrm{I}}_{\mathrm{x}}\right\}\right]-\left[{\mathrm{G}}_{\mathrm{sol}}\left\{\mathrm{E}:{\mathrm{I}}_{\mathrm{ref}}\right\}-{\mathrm{G}}_{\mathrm{sol}}\left\{{\mathrm{I}}_{\mathrm{ref}}\right\}\right]\left(11\right).$

^{[d]}$\u2206\u2206{\mathrm{TS}}_{\mathrm{vib}}$ represents the relative entropic contribution of the inhibitor to the GFE related to the E:I complex:$\u2206\u2206{\mathrm{TS}}_{\mathrm{vib}}=\left[\u2206\u2206{\mathrm{TS}}_{\mathrm{vib}}{\left\{{\mathrm{I}}_{\mathrm{x}}\right\}}_{\mathrm{E}}-\u2206\u2206{\mathrm{TS}}_{\mathrm{vib}}\left\{{\mathrm{I}}_{\mathrm{x}}\right\}\left]-\right[\u2206\u2206{\mathrm{TS}}_{\mathrm{vib}}{\left\{{\mathrm{I}}_{\mathrm{ref}}\right\}}_{\mathrm{E}}-\u2206\u2206{\mathrm{TS}}_{\mathrm{vib}}\left\{{\mathrm{I}}_{\mathrm{ref}}\right\}\right]\left(12\right)$.

^{[e]}$\u2206\u2206{\mathrm{G}}_{\mathrm{com}}$ represents the relative GFE change related to the enzyme-inhibitor complex formation: (see Equation (9)).

^{[f]}${\mathrm{IC}}_{50}^{\mathrm{exp}}$ [24] represents the inhibitor concentration that causes 50% decrease in the rate of substrate conversion by FP3 measured in the enzyme assay: ${\mathrm{pIC}}_{50}^{\mathrm{exp}}=-{\mathrm{log}}_{10}\frac{{\mathrm{IC}}_{50}^{\mathrm{exp}}}{{10}^{9}}$.

^{[g]}This is the ratio of the predicted activity on the experimental activity, ${\mathrm{pIC}}_{50}^{\mathrm{pre}}/{\mathrm{pIC}}_{50}^{\mathrm{exp}}$. This ratio is close to 1, indicating the predictivity of the QSAR model.

**Table 3.**Statistical data of correlation between computed $\u2206\u2206{\mathrm{G}}_{\mathrm{com}}$ ${\mathrm{IC}}_{50}^{\mathrm{exp}}$ of the training set.${\mathrm{pIC}}_{50}^{\mathrm{exp}}=-{\mathrm{log}}_{10}\left({\mathrm{IC}}_{50}^{\mathrm{exp}}\times {10}^{-9}\right)=-0.4794\times \u2206\u2206{\mathrm{G}}_{\mathrm{com}}+4.0455$.

Statistical Data of Linear Regression | |
---|---|

Number of compounds n | 9 |

$\mathrm{Squared}\mathrm{correlation}\mathrm{coefficient}\mathrm{of}\mathrm{regression}{\mathrm{R}}^{2}$ | $0.89$ |

$\mathrm{Leave}-\mathrm{one}-\mathrm{out}\mathrm{cross}-\mathrm{validated}\mathrm{squared}\mathrm{correlation}\mathrm{Coefficient}{\mathrm{R}}_{\mathrm{xv}}^{2}$ | $0.81$ |

$\mathrm{Standard}$ | $0.34$ |

Statistical significance of regression, Fisher F-test | 58.58 |

Level of statistical significance α | $>95\%$ |

$\mathrm{Range}\mathrm{of}\mathrm{activities}\mathrm{of}{\mathrm{IC}}_{50}^{\mathrm{exp}}$(nM) | 60–47,230 |

**Table 4.**Output parameters of 10 generated PH4 pharmacophoric hypotheses for FP3 inhibitors after Cat-Scramble validation procedure (49 scrambled runs for each hypothesis at the selected level of confidence of 98%).

Hypothesis | RMSD ^{[a]} | R^{2 [b]} | Total Costs ^{[c]} | Costs Difference ^{[d]} | Closest Random ^{[e]} |
---|---|---|---|---|---|

Hypo 1 | 0.795 | 0.999 | 24.13 | 2293.1 | 31.20 |

Hypo 2 | 2.958 | 0.991 | 60.64 | 2256.6 | 31.90 |

Hypo 3 | 3.623 | 0.987 | 80.35 | 2236.9 | 39.75 |

Hypo 4 | 4.907 | 0.976 | 130.37 | 2186.9 | 42.21 |

Hypo 5 | 5.128 | 0.974 | 139.89 | 2177.4 | 44.21 |

Hypo 6 | 5.203 | 0.973 | 143.71 | 2173.5 | 45.02 |

Hypo 7 | 5.880 | 0.966 | 177.49 | 2139.8 | 45.02 |

Hypo 8 | 7.910 | 0.937 | 304.23 | 2013.0 | 45.03 |

Hypo 9 | 9.767 | 0.902 | 451.68 | 1865.6 | 46.00 |

Hypo 10 | 9.830 | 0.901 | 456.44 | 1860.8 | 47.18 |

^{[a]}root mean square deviation;

^{[b]}squared correlation coefficient;

^{[c]}overall cost parameter of the PH4 pharmacophore;

^{[d]}cost difference between null cost and hypothesis total cost;

^{[e]}lowest cost from 49 scrambled runs at a selected level of confidence of 98%. The fixed cost = 21.24, with RMSD = 0, the null cost = 2317.26, with RMSD = 22.65 and the configuration cost = 11.85.

**Table 5.**Statistical data on regression analysis of correlation for the training set between PH4 predicted activity (${\mathrm{pIC}}_{50}^{\mathrm{pre}}$ ) and experimental one (${\mathrm{pIC}}_{50}^{\mathrm{exp}}$) against FP3.${\mathrm{pIC}}_{50}^{\mathrm{exp}}=-{\mathrm{log}}_{10}\left({\mathrm{IC}}_{50}^{\mathrm{exp}}\times {10}^{-9}\right)=1.0002\times {\mathrm{pIC}}_{50}^{\mathrm{pre}}-0.0012$.

Statistical Data of Linear Regression | |
---|---|

Number of compounds n | 9 |

$\mathrm{Squared}\mathrm{correlation}\mathrm{coefficient}\mathrm{of}\mathrm{regression}{\mathrm{R}}^{2}$ | $0.99$ |

$\mathrm{Leave}-\mathrm{one}-\mathrm{out}\mathrm{cross}-\mathrm{validated}\mathrm{squared}\mathrm{correlation}\mathrm{Coefficient}{\mathrm{R}}_{\mathrm{xv}}^{2}$ | $0.$99 |

$\mathrm{Standard}$ | 0.04 |

Statistical significance of regression, Fisher F-test | 5675.56 |

Level of statistical significance α | $>98\%$ |

$\mathrm{Range}\mathrm{of}\mathrm{activities}\mathrm{of}{\mathrm{IC}}_{50}^{\mathrm{exp}}$(nM) | 60–47,230 |

**Table 6.**R-groups (amino acid side chains) used in the design of the initial diversity library of PEP analogues. Dashed bonds indicate the attachment points of the fragments.

1 [Gly] | –H | 2 [Ala] | –CH_{3} | 3 [Val] | –CH(CH_{3})_{2} | 4 [Leu] | –CH_{2}-CH(CH_{3})_{2} |

5 [Ile] | –C(CH_{3})–C_{2}H_{5} | 6 [Met] | –-(CH_{2})_{2}–S–CH_{3} | 7 [Cys] | –CH_{2}–SH | 8 [Ser] | –CH_{2}–OH |

9 [Thr] | –CH(OH)-CH_{3} | 10 [Asp] | –CH_{2}–COOH | 11 [Glu] | –(CH_{2})_{2}–COOH | 12 [Asn] | –CH_{2}–CONH_{2} |

13 [Gln] | –(CH_{2})_{2}–CONH_{2} | 14 [Lys] | –(CH_{2})_{4}–NH_{2} | 15 [Arg] | –(CH_{2})_{3}–NH–C(NH)-NH_{2} | 16 [His] | |

17 [Phe] | 18 [Tyr] | 19 [Trp] |

**Table 7.**Complexation Gibbs free energy and its components for the top 21 scoring virtually designed analogues. The analogue numbering concatenates the index of each substituent R1 to R4 numbered in Table 6.

Analogues ^{[a]} | ${\mathbf{M}}_{\mathbf{W}}{}^{\left[\mathbf{b}\right]}$ | $\mathbf{\u2206}\mathbf{\u2206}{\mathbf{H}}_{\mathbf{M}\mathbf{M}}{}^{\left[\mathbf{c}\right]}$ | $\mathbf{\u2206}\mathbf{\u2206}{\mathbf{G}}_{\mathbf{s}\mathbf{o}\mathbf{l}}{}^{\left[\mathbf{d}\right]}$ | $\mathbf{\u2206}\mathbf{\u2206}\mathbf{T}{\mathbf{S}}_{\mathbf{v}\mathbf{i}\mathbf{b}}{}^{\left[\mathbf{e}\right]}$ | $\mathbf{\u2206}\mathbf{\u2206}{\mathbf{G}}_{\mathbf{c}\mathbf{o}\mathbf{m}}{}^{\left[\mathbf{f}\right]}$ | $\mathbf{I}{\mathbf{C}}_{50}^{\mathbf{p}\mathbf{r}\mathbf{e}}\left(\mathbf{nM}\right){}^{\left[\mathbf{g}\right]}$ |
---|---|---|---|---|---|---|

PEP23 | 482.61 | 0.00 | 0.00 | 0.00 | 0.00 | 36,360 |

PEP-14-19-04-01 | 400.53 | 5.54 | −6.82 | 0.75 | −2.03 | 9580.30 |

PEP-15-04-17-01 | 389.50 | −1.05 | −6.59 | 0.72 | −8.36 | 8.76 |

PEP-15-04-18-01 | 405.50 | −4.11 | −1.27 | 1.32 | −6.69 | 55.75 |

PEP-05-12-19-03 | 428.54 | −5.96 | 1.25 | 1.43 | −6.14 | 102.41 |

PEP-15-04-17-03 | 431.58 | −6.25 | −2.27 | 2.78 | −11.30 | 0.34 |

PEP-18-05-14-03 | 419.57 | −6.60 | −1.08 | 2.02 | −9.70 | 2.00 |

PEP-01-19-18-04 | 435.53 | −5.83 | -2.45 | −1.49 | −6.79 | 49.62 |

PEP-18-19-15-04 | 534.66 | −5.78 | −6.88 | −2.56 | −10.10 | 1.29 |

PEP-17-03-14-10 | 405.50 | −7.71 | −1.01 | 2.73 | −11.45 | 0.29 |

PEP-04-07-19-14 | 446.62 | −7.68 | 4.89 | 1.27 | −4.07 | 1009.94 |

PEP-17-09-19-15 | 506.61 | −12.07 | 11.41 | 2.83 | −3.49 | 1906.57 |

PEP-04-06-05-17 | 420.62 | −5.31 | −2.99 | 0.55 | −8.85 | 5.13 |

PEP-05-03-18-18 | 454.57 | −1.58 | −0.74 | 0.57 | −2.90 | 3676.95 |

PEP-14-14-14-18 | 463.63 | −9.46 | −2.40 | 0.91 | −12.76 | 0.07 |

PEP-02-15-03-19 | 428.54 | −3.28 | −2.99 | 1.78 | −8.05 | 12.35 |

PEP-03-08-15-19 | 444.54 | −2.26 | −5.00 | −0.81 | −6.45 | 72.74 |

PEP-08-15-17-19 | 492.58 | −9.89 | −0.26 | 0.54 | −10.69 | 0.67 |

PEP-08-15-18-19 | 508.58 | −12.30 | 0.84 | 0.38 | −11.83 | 0.19 |

PEP-09-18-18-19 | 529.60 | −7.61 | −0.28 | −0.19 | −7.70 | 18.29 |

PEP-10-18-18-19 | 543.58 | −10.16 | −0.81 | 0.19 | −11.15 | 0.40 |

PEP-13-06-04-19 | 474.63 | −10.05 | −1.60 | 0.76 | −12.42 | 0.10 |

^{[a]}Designed analogues;

^{[b]}M

_{W}represents molecular mass of the inhibitor;

^{[c]}$\u2206\u2206{\mathrm{H}}_{\mathrm{MM}}$ represents the relative enthalpic contribution to the Gibbs free energy change related to the FP3-PEP complex formation $\u2206\u2206{\mathrm{G}}_{\mathrm{com}}$;

^{[d]}$\u2206\u2206{\mathrm{G}}_{\mathrm{sol}}$ represents the relative solvation Gibbs free energy contribution to $\u2206\u2206{\mathrm{G}}_{\mathrm{com}}$;

^{[e]}$\u2206\u2206{\mathrm{TS}}_{\mathrm{vib}}$ represents the relative entropic (vibrational) contribution to $\u2206\u2206{\mathrm{G}}_{\mathrm{com}}$;

^{[f]}$\u2206\u2206{\mathrm{G}}_{\mathrm{com}}$ represents the relative Gibbs free energy change related to the enzyme-inhibitor FP3-PEP complex formation (see Equation (9));

^{[g]}${\mathrm{IC}}_{50}^{\mathrm{pre}}$ represents the predicted inhibition constant towards PfFP3 calculated from $\u2206\u2206{\mathrm{G}}_{\mathrm{com}}$ using correlation (Table 3).

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

## Share and Cite

**MDPI and ACS Style**

Bekono, B.D.; Esmel, A.E.; Dali, B.; Ntie-Kang, F.; Keita, M.; Owono, L.C.O.; Megnassan, E.
Computer-Aided Design of Peptidomimetic Inhibitors of Falcipain-3: QSAR and Pharmacophore Models. *Sci. Pharm.* **2021**, *89*, 44.
https://doi.org/10.3390/scipharm89040044

**AMA Style**

Bekono BD, Esmel AE, Dali B, Ntie-Kang F, Keita M, Owono LCO, Megnassan E.
Computer-Aided Design of Peptidomimetic Inhibitors of Falcipain-3: QSAR and Pharmacophore Models. *Scientia Pharmaceutica*. 2021; 89(4):44.
https://doi.org/10.3390/scipharm89040044

**Chicago/Turabian Style**

Bekono, Boris D., Akori E. Esmel, Brice Dali, Fidele Ntie-Kang, Melalie Keita, Luc C. O. Owono, and Eugene Megnassan.
2021. "Computer-Aided Design of Peptidomimetic Inhibitors of Falcipain-3: QSAR and Pharmacophore Models" *Scientia Pharmaceutica* 89, no. 4: 44.
https://doi.org/10.3390/scipharm89040044